“Metachromatic Leukodystrophy Market” report has been added to DelveInsight
Metachromatic Leukodystrophy disease Overview
Metachromatic Leukodystrophy (MLD) is a rare inherited disorder characterized by the accumulation of fats called sulfatides in cells. This accumulation especially affects cells in the nervous system that produce myelin, the substance that insulates and protects nerves. Nerve cells covered by myelin make up a tissue called white matter. This condition is called metachromatic leukodystrophy because when viewed under a microscope, sulfatide accumulation in cells appears as granules that are colored differently than other cellular material (metachromatic).
Get a free sample copy now- https://www.delveinsight.com/sample-request/metachromatic-leukodystrophy-mld-market
Metachromatic Leukodystrophy Market: Geography Covered
Metachromatic Leukodystrophy Market Companies
Metachromatic Leukodystrophy Drugs
Metachromatic Leukodystrophy Market Report
MLD is caused due to mutations in the ARSA gene, which provides instructions for making the enzyme arylsulfatase A. This enzyme is located in cellular structures called lysosomes, which are the cell’s recycling centres. Within lysosomes, arylsulfatase A helps break down sulfatides. A few individuals with metachromatic leukodystrophy have mutations in the PSAP gene. This gene provides instructions for making a protein that is broken up (cleaved) into smaller proteins that assist enzymes in breaking down various fats. One of these smaller proteins is called saposin B; this protein works with arylsulfatase A to break down sulfatides.
Metachromatic Leukodystrophy Market Research
There are three types of MLD based on the age symptoms appear: late-infantile MLD, juvenile MLD, and adult MLD. All subtypes ultimately affect both intellectual and motor function. Symptoms vary by type but can include ataxia, behavioural abnormality, behavioural changes, coma, decreased nerve conduction velocity, intellectual disability, muscle weakness, neurological speech impairment, seizures, joint stiffness, reduced tendon reflexes, spasticity, abnormal muscle movements, difficulty walking, irritability, swallowing difficulty, etc.
Metachromatic Leukodystrophy Market Report Highlights
Metachromatic Leukodystrophy Market Insights
Table of content
1. Key Insights
2. Executive Summary of Metachromatic Leukodystrophy (MLD)
3. Competitive Intelligence Analysis for Metachromatic Leukodystrophy (MLD)
4. Metachromatic Leukodystrophy (MLD) : Market Overview at a Glance
5. Metachromatic Leukodystrophy (MLD) : Disease Background and Overview
6. Patient Journey
7. Metachromatic Leukodystrophy (MLD) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Metachromatic Leukodystrophy (MLD) Treatment
11. Marketed Products
12. Emerging Therapies
13. Metachromatic Leukodystrophy (MLD) : Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Metachromatic Leukodystrophy (MLD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
In conclusion, this report provides information such as causes, symptoms, treatment, and Market report, Market Research, Market Drivers, Market Barriers and SWOT Analysis are also incorporated in the report
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/